Abstract

ABSTRACTMitochondrial dynamics is a highly dysregulated process in cancer. Apoptosis and mitochondrial fission are two concurrent events wherein increased mitochondrial fragmentation serves as a hallmark of apoptosis. We have shown earlier that miR-195 exerts pro-apoptotic effects in breast cancer cells. Herein, we have demonstrated miR-195 as a modulator of mitochondrial dynamics and function. Imaging experiments upon miR-195 treatment have shown that mitochondria undergo extensive fission. We validated mitofusin2 as a potential target of miR-195. This may provide a molecular explanation for the respiratory defects induced by miR-195 over-expression in breast cancer cells. Active, but not total, mitochondrial mass, was reduced with increasing levels of miR-195. We have further shown that miR-195 enhances mitochondrial SOD-2 expression but does not affect PINK1 levels in breast cancer cells. Collectively, we have revealed that miR-195 is a modulator of mitochondrial dynamics by targeting MFN2 thereby impairing mitochondrial function. Concomitantly, it enhances the scavenger of reactive oxygen species (SOD-2) to maintain moderate levels of oxidative stress. Our findings suggest a therapeutic potential of miR-195 in both ER-positive as well as ER-negative breast cancer cells.

Highlights

  • Breast cancer is one of the leading causes of death in women worldwide

  • We have previously shown that MiR-195 over-expressed using p195 plasmid construct (miR-195) was upregulated using pSilencermiR-195 (miR)-195 affects mitochondrial function by means of depolarization of the inner membrane and disturbing calcium homeostasis within the organelle [17]

  • The luciferase activity was reduced by 0.4 fold (p-value

Read more

Summary

Introduction

Breast cancer is one of the leading causes of death in women worldwide. Treatment of breast cancer includes radiation, surgery and chemotherapy. The majority of breast tumours are hormone-dependent, and they account for about 70% of breast cancers. PR-positive are much more likely to respond to hormone therapy than tumours that are ER/PR-negative.Triple negative breast cancer (TNBC) lacks all three receptors i.e.ER, PR, and Her. The Cancer therapy that targets these receptors does not work well with TNBC tumour [2]. The development of drug resistance to chemotherapy is one of the major hurdles in treatment of breast cancer [3]. Development of novel drugs that target tumours irrespective of their hormone receptor status has a potential to strengthen the fight against breast cancer

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call